Somsak PrasongtanakijUsanarat AnurathapanThitinee VanichapolBunyada JittorntrumKorakot AtjanasuppatPongpak PongpitchaSamart PakakasamaDuantida SongdejNongnuch SirachainanKaran PaisooksantivatanaSuparerk BorwaornpinyoBorje S. AnderssonSuradej HongengFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityUniversity of Texas MD Anderson Cancer CenterMahidol University2020-10-052020-10-052020-01-01Asia-Pacific Journal of Clinical Oncology. (2020)17437563174375552-s2.0-85091348722https://repository.li.mahidol.ac.th/handle/20.500.14594/59279© 2020 John Wiley & Sons Australia, Ltd Aims: The purpose of this study was to design and manufacture CD19 chimeric antigen receptor (CAR)-modified T cells for clinical use in Thailand, as a model for how this technology can be directly applied at individual institutions treating high-risk leukemia patients. Methods: We constructed second-generation CAR T cells expressing CD19 scFV-CD28-CD3ζ with different lengths of the spacer region: full, intermediate, and short length, by using a lentiviral vector. We wanted to determine whether the difference in length of the spacer would affect the cytotoxic potential of the CD19 CAR T cells against the leukemic cells. Results: We found that all constructs of CD19 CAR T cells exhibited a similar level of cytotoxicity against several human lymphoma and leukemia cell lines. For the clinical application, we chose the intermediate length spacer construct CD19 CAR T cells, hypothesizing that the highest transduction efficiency coupled with a slower initial proliferation in vitro might lead to effective leukemic cell kill, yet a lower probability for serious clinical side effects. We then tested the clinical efficacy of our CD19 CAR T cells in one patient with refractory/relapsed acute B-cell lymphoblastic leukemia. This patient indeed had minimal clinical side effects after the CAR T-cell infusion, and he remains in an unmaintained, ongoing complete remission 10+ months after his T-cell treatment. Conclusion: Our CD19 CAR T cells demonstrated efficacies in acute lymphoblastic B-cell leukemia, and will be used to establish an immunotherapeutic program for high-risk B-cell acute lymphoblastic leukemia in Thailand. We propose that this approach can be used as a model for how this new exciting technology can be applied directly at individual institutions that treat (a large number of) patients with high-risk leukemia.Mahidol UniversityMedicineArticleSCOPUS10.1111/ajco.13474